Active substanceIbuprofenIbuprofen
Similar drugsTo uncover
  • Advil®
    pills inwards 
  • Advil® for children
    suspension inwards 
  • Advil Maximum®
    capsules inwards 
  • Bonifen
    pills inwards 
  • Brudol® for children
    suppositories d / children rect. 
  • Brufen SR
    pills inwards 
    Abbott GmbH & Co. KG     Germany
  • Deblock
    pills inwards 
    Alkaloid, JSC     Macedonia
  • Deep Relief
    gel externally 
    Mentolatum Company Limited     United Kingdom
  • Dolgit®
    gel externally 
  • Dolgit®
    cream externally 
  • Ibuprofen
    suppositories d / children rect. 
    RAFARMA, CJSC     Russia
  • Ibuprofen
    pills inwards 
  • Ibuprofen
    pills inwards 
  • Ibuprofen
    suppositories inwards d / children 
    ECOLAB, CJSC     Russia
  • Ibuprofen
    ointment externally 
    BIOCHEMIST, OJSC     Russia
  • Ibuprofen
    pills inwards 
  • Ibuprofen
    gel externally 
    ATOLL, LLC     Russia
  • Ibuprofen
    pills inwards 
    Zentiva c.s.     Czech Republic
  • Ibuprofen
    suspension inwards d / children 
  • Ibuprofen for children
    suppositories d / children rect. 
    PATENT-FARM, CJSC     Russia
  • Ibuprofen Sandoz®
    pills inwards 
    Sandoz d.     Slovenia
  • Ibuprofen-Akrihin
    suspension inwards d / children 
  • Ibuprofen-Akrihin
    suppositories rect. d / children 
  • Ibuprofen-Verte
    gel externally 
    VERTEKS, AO     Russia
  • Ibuprofen-Hemofarm
    pills inwards 
    Hemofarm AD     Serbia
  • Ibuprofen-Hemofarm
    pills inwards 
    Hemofarm AD     Serbia
  • Maxikold® for children
    suspension inwards 
    OTISIFARM, OJSC     Russia
  • MIG® 400
    pills inwards 
  • MIG® for children
    suspension inwards 
    Berlin-Chemie, AG     Germany
  • MIG® for babies
    suspension inwards 
    Berlin-Chemie, AG     Germany
  • Neboline® capsules
    capsules inwards 
    Alvogen IPKo S.A.L.     Luxembourg
  • Next-Uno Express
    capsules inwards 
    OTISIFARM, OJSC     Russia
  • Nurofen®
    pills inwards 
  • Nurofen® Rapid Forte
    pills inwards 
  • Nurofen® forte
    pills inwards 
  • Nurofen® Express
    capsules inwards 
  • Nurofen® Express
    pills inwards 
  • Nurofen® Express
    gel externally 
  • Nurofen® Express Neo
    pills inwards 
  • Nurofen® Express Forte
    capsules inwards 
  • Pedee®
    solution in / in 
    Orphan Europe     France
  • Sedalgin® SPRINT
    capsules inwards 
    Aktavis Ltd.     Iceland
  • Solphaflex
    pills inwards 
  • Faspik
    granules inwards 
  • Dosage form: & nbspcapsules
    Composition:

    One capsule of 200.0 mg contains:

    active substance: ibuprofen 200.0 mg;

    Excipients: macrogol 400 220.0 mg, sorbitol solution 70% 20.0 mg, sorbitan oleate 10.0 mg, potassium hydroxide 25.0 mg, water 25.0 mg.

    shell capsules: gelatin 127.48 mg, macrogol 400 0.3 mg, sorbitol solution 70% 35.61 mg, dye crimson (Ponso 4R) 0.18 mg, water 34.93 mg, triglycerides medium chain (traces), white opaque ink (S -1-7305 HV) (glaze [shellac solution 45%], titanium dioxide, water, n-butanol, soy lecithin, antifoam agent DC 1510-US) - qs

    One 400.0 mg capsule contains:

    active substance: ibuprofen 400.0 mg;

    Excipients: macrogol 400 200.0 mg, sorbitol solution 70% 30.0 mg, sorbitan oleate 20.0 mg, potassium hydroxide 35.0 mg, water 35.0 mg.

    shell capsules: gelatin 170.08 mg, macrogol 400 0.4 mg, sorbitol solution 70% 71.3 mg, water 21.0 mg, medium chain (trace) triglycerides, opacode black ink (S-1-17823) (shellac, isopropanol, dye iron oxide black, p-butanol, propylene glycol, ammonium hydroxide) - qs

    Description:

    Capsules 200 mg: soft translucent gelatin capsules of the oval form of dark red color with the inscription "200" with white ink.

    The contents of capsules are a viscous transparent liquid from colorless to pinkish-red.

    Capsules 400 mg: soft translucent gelatin capsules of the oval form from colorless to light yellow color with an inscription "400" black ink.

    The contents of the capsules are a viscous clear liquid from colorless to light yellow in color.

    Pharmacotherapeutic group:Non-steroidal anti-inflammatory drug (NSAID)
    ATX: & nbsp

    M.01.A.E.01   Ibuprofen

    Pharmacodynamics:Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID). Has anti-inflammatory, analgesic and antipyretic effect. The mechanism of action is associated with the indiscriminate blocking of cyclooxygenase (COX) COX1 and COX2, the main enzyme of arachidonic acid metabolism, which is the precursor of prostaglandins, mediators of inflammation, pain and hyperthermia.
    Pharmacokinetics:

    Ibuprofen is almost completely absorbed from the gastrointestinal tract. With blood plasma proteins bind more than 90%.

    Cmax ibuprofen in blood plasma is achieved after 1-2 hours, and in this dosage form can be reached after 40 minutes. Slowly penetrates into the joint cavity, is retained in the synovial fluid, creating in it greater concentrations than in the plasma.

    Ibuprofen is metabolized in the liver with the formation of two pharmacologically inactive derivatives. Metabolites and their conjugates, together with unchanged ibuprofen, are excreted by the kidneys (unchanged not more than 1%) and, to a lesser extent, bile. T1/2 (half-life) is 2-3 hours.

    Indications:

    Adults and children over 12 years.

    The drug is indicated for symptomatic relief of headache, toothache, migraine, pain with dysmenorrhea (menstrual pain), neuralgia, back pain, rheumatic, muscular and other types of pain; feverish conditions for influenza and colds.

    Contraindications:

    - Hypersensitivity to the active substance (ibuprofen) or any auxiliary component of the drug.

    - A complete or incomplete syndrome of intolerance to acetylsalicylic acid or other NSAIDs (rhinosinusitis, urticaria, bronchial asthma, recurrent polyps of the nasal mucosa and paranasal sinuses, including in the anamnesis).

    - Erosive and ulcerative diseases of the organs of the gastrointestinal tract in the stage of exacerbation (including erosive and ulcerative lesions of the gastrointestinal tract and duodenum, Crohn's disease, nonspecific ulcerative colitis).

    - Severe liver failure or active liver disease.

    - Severe renal failure (creatinine clearance (CK) less than 30 ml / min), progressive kidney disease, confirmed hyperkalemia.

    Decompensated heart failure.

    - Hemophilia and other disorders of blood clotting (including hypocoagulation), hemorrhagic diathesis.

    - Gastrointestinal bleeding and intracranial hemorrhage.

    - Period after aortocoronary bypass surgery.

    - Pregnancy III trimester.

    - Children under 12 years.

    - Deficiency of sugar / isomaltase, intolerance to fructose, glucose-galactose malabsorption (due to the presence of sorbitol in the composition).

    Carefully:In old age, with heart failure, arterial hypertension, coronary heart disease, cerebrovascular diseases, dyslipidemia / hyperlipidaemia, diabetes, peripheral arterial diseases, smoking, frequent use of alcohol, liver cirrhosis with portal hypertension, creatinine clearance 30-60 ml / min, hepatic and / or renal failure, nephrotic syndrome, hyperbilirubinemia, liver history, liver porphyria, peptic ulcer and duodenal ulcer (in anamnesis e), gastritis, enteritis, colitis, infection of Helicobacter pylori (H. Pylori), blood diseases of unclear etiology (leukopenia and anemia), the period of breastfeeding,prolonged use of NSAIDs, severe somatic diseases, the oral simultaneous administration of glucocorticosteroids (GCS) (including prednisone), anticoagulants (including warfarin), antiplatelet agents (including acetylsalicylic acid, clopidogrel), selective inhibitors of reverse serotonin (including citalopram, fluoxetine, paroxetine, sartralina), a significant decrease in the circulating blood volume (including after surgery), asthma, systemic lupus erythematosus or other systemic diseases with dinitelnoy tissue.
    Pregnancy and lactation:

    Pregnancy:

    The use in the first and second trimesters of pregnancy is justified only in cases where the expected benefit for the mother exceeds the possible harm to the fetus.

    In the third trimester of pregnancy use of ibuprofen is contraindicated as there is a risk of premature closure of the ductus arteriosus in the fetus with possible development of persistent pulmonary hypertension. The onset of labor can be delayed, and the duration of labor is increased with the tendency to develop extensive bleeding in both the mother and the child.

    Breastfeeding period:

    It is not recommended to use during breastfeeding due to the limited information available on the penetration of ibuprofen into breast milk in very low doses.

    Dosing and Administration:

    Inside, washed down with a small amount of water, in capsules of 200 mg 3-4 times a day, in capsules of 400 mg 3 times a day.

    The interval between taking two doses of the drug should be at least 4 hours. Do not take more than 3 400 mg capsules for 24 hours. The maximum daily dose for adults is 1200 mg. The maximum daily dose for children from 12 to 17 years is 800 mg.

    If symptoms persist for 2-3 days after taking the drug, stop treatment and consult a doctor.

    Side effects:

    In each frequency group, undesirable drug reactions are listed in order of decreasing significance. Estimated incidence of adverse reactions is based on the following criteria: very frequent (≥ 1/10), frequent (≥ 1/100 to <1/10), infrequent (from ≥ 1/1000 to <1/100), rare from ≥ 1/10 000 to <1/1000), very rare (<1/10 000), the frequency is unknown (according to available data, it was not possible to establish the frequency of occurrence).

    When using ibuprofen for 2-3 days, side effects are very rare.In the case of prolonged use, the following side effects may occur:

    From the gastrointestinal tract:

    Infrequent: NSAIDs-gastropathy (abdominal pain, nausea, heartburn, loss of appetite),

    rare: vomiting, diarrhea, flatulence, constipation,

    very rare: ulceration of the mucosa (on the part of the gastrointestinal tract), which in some cases is complicated by perforation and bleeding); irritation or dryness of the oral mucosa, pain in the mouth, ulceration of the gingival mucosa, aphthous stomatitis, pancreatitis.

    From the respiratory system, chest and mediastinum:

    Very rare: shortness of breath, bronchospasm.

    From the sense organs:

    Very rare: hearing impairment: hearing loss, "ringing or tinnitus"; visual impairment: toxic damage to the optic nerve, blurred vision or double vision, scotoma, dryness and irritation of the eyes, edema of the conjunctiva and eyelids (allergic genesis).

    From the central and peripheral nervous system:

    Infrequent: headache, dizziness,

    very rare: insomnia, anxiety, nervousness and irritability, psychomotor agitation, drowsiness, depression, confusion, hallucinations, rarely aseptic meningitis (more often in patients with autoimmune diseases).

    From the cardiovascular system:

    Very rare: heart failure, tachycardia, increased blood pressure.

    From the liver and bile ducts:

    Very rarely: hepatitis.

    From the side of the kidneys and urinary tract:

    Rare: acute renal failure, allergic nephritis, nephrotic syndrome (edema), polyuria, cystitis.

    From the skin and subcutaneous tissues:

    Infrequent: skin rash (usually erythematous or urticaria), itchy skin,

    very rare: angioedema, anaphylactoid reactions, anaphylactic shock, bronchoconstriction or dyspnea, fever, erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), eosinophilia, allergic rhinitis.

    From the side of the blood and lymphatic system:

    Rare: anemia (including haemolytic, aplastic), thrombocytopenia and trombotsitoienicheskaya purpura, agranulocytosis, leukopenia.

    Laboratory and instrumental data:

    - Bleeding time (may increase),

    - concentration of glucose in the serum (may decrease),

    - clearance of creatinine (may decrease),

    -hematocrit or hemoglobin (may decrease),

    - serum creatinine concentration (may increase),

    - activity of "liver transaminases" (may increase).

    If side effects occur, stop taking the medication and consult a doctor.

    Overdose:

    Symptoms of drug overdose:

    Abdominal pain, nausea, vomiting, retardation, drowsiness, depression, headache, tinnitus, metabolic acidosis, coma, acute renal failure, lowering of blood pressure, bradycardia, tachycardia, atrial fibrillation, respiratory arrest.

    Treatment and care:

    Gastric lavage (only within an hour after administration), Activated carbon, alkaline drink, forced diuresis, symptomatic therapy.

    Interaction:

    In connection with the description of a number of clinical observations, care should be taken when prescribing to patients taking any of the following drugs:

    - Acetylsalicylic acid or other NSAIDs may increase the risk of side effects. Care should be taken if acetylsalicylic acid is taken with coronary artery disease or cerebral circulation disorders, because ibuprofen can reduce the therapeutic effect of acetylsalicylic acid.

    - Hypotensive drugs and diuretics: ibuprofen can weaken the effects of these drugs. Diuretics can increase the risk of nephroxicity associated with the use of ibuprofen.

    - Cardiac glycosides: NSAIDs can increase heart failure, reduce GFR (glomerular filtration rate) and increase the level of glycosides in blood plasma.

    - Some antacids may reduce the absorption of ibuprofen from the gastrointestinal tract, which may be important with prolonged administration of ibuprofen.

    - Corticosteroids, these drugs may increase the risk of ulceration or development of bleeding in the gastrointestinal tract.

    - Anticoagulants: NSAIDs can enhance the effects of anticoagulants, such as warfarin.

    - Antiaggregants and selective serotonin reuptake inhibitors (SSRIs): increased risk of developing gastrointestinal bleeding.

    - Lithium preparations: there are data on the possible increase in the level of lithium in blood plasma against the background of the use of ibuprofen.

    - Methotrexate: there is evidence of a possible increase in the level of methotrexate in blood plasma when NSAIDs are applied.

    - Cyclosporine and preparations of gold: increased risk of nephrotoxicity.

    - Mifepristone: NSAIDs should not be used within 8-12 days after the administration of mifepristone, because as NSAIDs may reduce the therapeutic effect of mifeprisgone.

    - Tacrolimus: a possible increased risk of nephrotoxicity in combined use of NSAIDs and tacrolimus.

    - Zidovudine: increased risk of hematologic toxicity when combined with NSAIDs and zidovudine. There is evidence of an increased risk of hemarthrosis and hematoma in HIV-infected patients with hemophilia who receive concomitant treatment with zidovudine and ibuprofen.

    - Antibiotics of a number of quinolones: patients taking NSAIDs and antibiotics of the quinolone range may have an increased risk of seizures.

    - Microsomal oxidation inductors (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites, increasing the risk of developing severe hepatotoxic reactions.

    - Inhibitors of microsomal oxidation reduce the risk of hepatotoxic action.

    - Caffeine strengthens the analgesic effect.

    - Cefamandol, cefoperazone, cefotetan, valproic acid, plikamycin increase the frequency of hypoprothrombinemia.

    - Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.

    - Kolestyramine reduces the absorption of ibuprofen.

    Special instructions:

    Undesirable effects can be minimized when the drug is administered at the lowest effective dose for the shortest period of time necessary to control the symptoms (see above gastrointestinal (GI) and cardiovascular) risks.

    In elderly people there is an increased incidence of adverse reactions with NSAIDs, especially gastrointestinal bleeding and perforation, which can be lethal to the patient.

    During long-term treatment, control of the peripheral blood picture and the functional state of the liver and kidneys is necessary. When symptoms of gastropathy appear, careful monitoring including esophagogastroduodenoscopy, a general blood test (determination of hemoglobin), and analysis of feces for latent blood are shown.

    If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the test.

    During the period of treatment, ethanol is not recommended.

    Effect on the ability to drive transp. cf. and fur:Patients taking the drug should refrain from activities that require increased concentration of attention and rapid mental and motor reactions.
    Form release / dosage:Capsules 200 mg, 400 mg.
    Packaging:

    For 10 or 12 capsules in a blister of Al / PVC or Al / PVDC.

    For 1 or 2 blisters together with instructions for use in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:3 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:LP-003293
    Date of registration:05.11.2015 / 17.01.2018
    Expiration Date:05.11.2020
    The owner of the registration certificate:Alvogen IPKo S.A.L.Alvogen IPKo S.A.L. Luxembourg
    Manufacturer: & nbsp
    Representation: & nbspAlvogen Pharma Trading EuropeAlvogen Pharma Trading Europe
    Information update date: & nbsp18.06.2018
    Illustrated instructions
      Instructions
      Up